Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

KEYNOTE-522: Phase 3 study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)

Date

29 Sep 2019

Session

Presidential Symposium II

Presenters

Peter Schmid

Citation

Annals of Oncology (2019) 30 (suppl_5): v851-v934. 10.1093/annonc/mdz394

Authors

P. Schmid1, J. Cortés2, R. Dent3, L. Pusztai4, H.L. McArthur5, S. Kuemmel6, J. Bergh7, C. Denkert8, Y.H. Park9, R. Hui10, N. Harbeck11, M. Takahashi12, T. Foukakis13, P.A. Fasching14, F. Cardoso15, L. Jia16, V. Karantza17, J. Zhao18, G. Aktan17, J. O'Shaughnessy19

Author affiliations

  • 1 Centre For Experimental Cancer Medicine, Barts Cancer Institute-Queen Mary University of London, EC1M 6BQ - London/GB
  • 2 Oncology Department, IOB Institute of Oncology, Quironsalud Group, Madrid & Barcelona & Vall d´Hebron Intitute of Oncology (VHIO), Barcelona, 28034 - Madrid/ES
  • 3 Division Of Medical Oncology, NCCS - National Cancer Centre Singapore, 169610 - Singapore/SG
  • 4 Yale Cancer Center, Yale University School of Medicine, 06520 - New Haven/US
  • 5 Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 90048 - Los Angeles/US
  • 6 Breast Unit, Kliniken Essen-Mitte Evang. Huyssens-Stiftung, 45136 - Essen/DE
  • 7 Department Of Oncology-pathology, Karolinska Institutet - Bioclinicum, 171 64 - Stockholm/SE
  • 8 Institute Of Pathology, Philipps University Marburg, 35043 - Marburg/DE
  • 9 Hematology-oncology, Samsung Medical Center Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR
  • 10 Department Of Medical Oncology, Westmead Hospital and the University of Sydney, 2145 - Sydney/AU
  • 11 Breast Center, Department Of Gynecology And Obstetrics, University of Munich (LMU), 81377 - Munich/DE
  • 12 Department Of Breast Surgery, NKO Hokkaido Cancer Center, 003-0804 - Sapporo/JP
  • 13 Oncology-pathology, Karolinska Institutet, 17164 - Solna/SE
  • 14 Gynecology And Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, 91054 - Erlangen/DE
  • 15 Breast Unit, Champalimaud Foundation Cancer Center, 1400-038 - Lisbon/PT
  • 16 Biostatistics, Merck & Co., Inc., 07033 - Kenilworth/US
  • 17 Department Of Oncology, Merck & Co., Inc., 07033 - Kenilworth/US
  • 18 Biostatistics, Merck & Co Inc, 19454 - North Wales/US
  • 19 Breast Oncology, Baylor University Medical Center, 75246 - Dallas/US
More

Resources

Background

Neoadjuvant pembro + chemo had manageable safety and promising antitumor activity in participants (pts) with early TNBC in KEYNOTE-173 and I-SPY 2. KEYNOTE-522 (NCT03036488) is a pbo controlled phase III study of neoadjuvant pembro + chemo followed by adjuvant pembro in pts with early TNBC.

Methods

Pts with previously untreated, non-metastatic, centrally confirmed TNBC (stage T1c N1-2 or T2-4 N0-2 per AJCC) were randomized 2:1 to pembro 200 mg Q3W or pbo, both given with 4 cycles of paclitaxel + carboplatin, then with 4 cycles of doxorubicin or epirubicin + cyclophosphamide (neoadjuvant phase). After definitive surgery, pts received pembro or pbo for 9 cycles or until recurrence or unacceptable toxicity (adjuvant phase). Pts were stratified by nodal status (+ vs -), tumor size (T1/T2 vs T3/T4), and carboplatin schedule (Q3W vs QW). Dual primary endpoints were pCR defined as ypT0/Tis ypN0 and event-free survival (EFS). Secondary endpoints included pCR defined as ypT0 ypN0 and ypT0/Tis, OS, and efficacy in the PD-L1+ population.

Results

Median follow-up was 15.5 mo (range, 2.7-25.0). 784 pts were randomized to pembro, 390 to pbo. Among 602 pts evaluable for the definitive pCR analysis, pembro + chemo showed a statistically significant improvement in pCR (ypT0/Tis ypN0) vs pbo + chemo: 64.8% (95% CI, 59.9-69.5) vs 51.2% (95% CI, 44.1-58.3), P = 0.00055; results were consistent for the secondary pCR definitions, ypT0 ypN0 (59.9% vs 45.3%) and ypT0/Tis (68.6% vs 53.7%). For pembro vs pbo, pCR (ypT0/Tis ypN0) was 68.9% vs 54.9% in the PD-L1+ population and 45.3% vs 30.3% in the PD-L1- population. The addition of pembro to chemo followed by pembro showed a favorable trend in EFS (HR 0.63 [95% CI, 0.43-0.93]). Across phases, grade 3 or higher treatment-related AE rates were 78.0% in the pembro + chemo group and 73.0% in the pbo + chemo group (death incidence, 0.4% vs 0.3%, respectively).

Conclusions

Addition of pembro to neoadjuvant chemo significantly increased the pCR rate in pts with early TNBC. Neoadjuvant pembro + chemo followed by adjuvant pembro showed a favorable trend in EFS. AEs were consistent with the known safety profiles of each agent.

Clinical trial identification

NCT03036488.

Editorial acknowledgement

Writing assistance was provided by Christine McCrary Sisk and funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Legal entity responsible for the study

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Funding

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Disclosure

P. Schmid: Honoraria (self): Pfizer, AZ, Novartis, Roche, Merck, BI, Bayer, Eisai, Puma, Celgene; Advisory / Consultancy: Pfizer, AZ, Novartis, Roche, Merck, BI, Bayer, Eisai, Puma, Celgene; Research grant / Funding (institution): AZ, Genetech, Roche, Oncogenex, Novaris, Astellas; Spouse / Financial dependant: Spouse is a consultant for Genetech/Roche. J. Cortés: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Honoraria (self), Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy: Celgene; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Eisai; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Pfizer; Honoraria (self): Samsung Bioepis; Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Merck Sharpe & Dohme; Advisory / Consultancy: Cellestia; Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy: Biothera Pharmaceuticals; Advisory / Consultancy: Merus; Advisory / Consultancy: Seattle Genetics; Advisory / Consultancy, Travel / Accommodation / Expenses: Daiichi Sankyo; Advisory / Consultancy: Erytech; Advisory / Consultancy: Athenex; Advisory / Consultancy: Polyphor; Advisory / Consultancy: Servier; Research grant / Funding (institution): Ariad Pharmaceuticals; Research grant / Funding (institution): Baxalta GMBH/Servier Affaires; Research grant / Funding (institution): Bayer Healthcare; Research grant / Funding (institution): Guardian Health; Research grant / Funding (institution): Piqur Therapeutics ; Research grant / Funding (institution): Puma C; Research grant / Funding (institution): Queen Mary University of London; Research grant / Funding (institution): Seagen; Shareholder / Stockholder / Stock options: MedSIR. R. Dent: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Travel / Accommodation / Expenses: Eisai; Advisory / Consultancy, Travel / Accommodation / Expenses: Merck; Advisory / Consultancy: Novartis; Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy, Travel / Accommodation / Expenses: Roche. L. Pusztai: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Genentech; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Eisai; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pieris; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Immunomedics; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Seattle Genetics; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Almac; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Syndax. H.L. McArthur: Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck; Advisory / Consultancy, Travel / Accommodation / Expenses: Spectrum Pharm; Advisory / Consultancy, Travel / Accommodation / Expenses: Lilly; Advisory / Consultancy, Travel / Accommodation / Expenses: Amgen; Advisory / Consultancy, Travel / Accommodation / Expenses: Immunomedics; Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy, Travel / Accommodation / Expenses: Genentech; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bristol-Myers Squibb; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Travel / Accommodation / Expenses: Puma Biotechnology. S. Kuemmel: Advisory / Consultancy: F. Hoffmann-La Roche Ltd; Advisory / Consultancy: Genomic Health; Advisory / Consultancy: Novartis; Advisory / Consultancy: Amgen; Advisory / Consultancy: Celgene; Advisory / Consultancy, Travel / Accommodation / Expenses: Daiichi Sankyo; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Somatex; Advisory / Consultancy: MSD; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Puma Biotechnology; Advisory / Consultancy: PFM Medical; Advisory / Consultancy: Lilly; Research grant / Funding (institution): WSG; Travel / Accommodation / Expenses: Roche Pharma. J. Bergh: Research grant / Funding (institution): Amgen; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Sanofi Aventis. C. Denkert: Honoraria (self): Teva; Honoraria (self): Novartis; Honoraria (self): Pfizer; Honoraria (self): Roche; Honoraria (self), Advisory / Consultancy: Amgen ; Advisory / Consultancy: MSD; Advisory / Consultancy: Daiichi Sankyo; Shareholder / Stockholder / Stock options: Sividon (Myriad); Licensing / Royalties: VmScope. Y.H. Park: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis; Advisory / Consultancy, Research grant / Funding (self): Eisai; Advisory / Consultancy, Research grant / Funding (self): Roche; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Merck; Research grant / Funding (self): AstraZeneca. R. Hui: Honoraria (self), Advisory / Consultancy: MSD; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Eli Lilly. N. Harbeck: Honoraria (institution): only research grants; Advisory / Consultancy: Agendia; Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy: Celgene; Advisory / Consultancy, Speaker Bureau / Expert testimony: Daiichi Sankyo; Advisory / Consultancy: Genomic Health; Advisory / Consultancy, Speaker Bureau / Expert testimony: Lilly; Advisory / Consultancy, Speaker Bureau / Expert testimony: MSD; Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis; Advisory / Consultancy: Odonate; Advisory / Consultancy, Speaker Bureau / Expert testimony: Pfizer; Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Advisory / Consultancy: Sandoz/Hexal; Advisory / Consultancy: Seattle Genetics; Speaker Bureau / Expert testimony: Amgen; Speaker Bureau / Expert testimony: Nanostring; Leadership role: German AGO Breast Committee; Research grant / Funding (institution): several phase II-III trials; Shareholder / Stockholder / Stock options: CO-Director West German Study Group; Full / Part-time employment: LMU Munich; Spouse / Financial dependant: West German Study Group. M. Takahashi: Honoraria (self): AstraZeneca; Honoraria (self): Pfizer; Honoraria (self): Eli Lilly ; Honoraria (self), Research grant / Funding (self): Eisai; Research grant / Funding (self): Taiho; Research grant / Funding (self): Kyowa-Hakko Kirin; Research grant / Funding (self): Nippon Kayaku . T. Foukakis: Honoraria (self), Honoraria (institution), Research grant / Funding (institution): Roche; Honoraria (self), Travel / Accommodation / Expenses: Novartis; Honoraria (institution), Research grant / Funding (institution): Pfizer; Licensing / Royalties: Wolters Kluwer Health (UpToDate). P.A. Fasching: Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution): Novartis; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Pfizer; Honoraria (self), Advisory / Consultancy: Celgene; Honoraria (self), Advisory / Consultancy: Daiichi-Sankyo; Honoraria (self), Advisory / Consultancy: TEVA; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Merck Sharp&Dohme; Honoraria (self), Advisory / Consultancy: Myelo Therapeutics; Honoraria (self), Advisory / Consultancy: Macrogenics; Honoraria (self), Advisory / Consultancy: Eisai; Honoraria (self), Advisory / Consultancy: Puma; Honoraria (institution), Research grant / Funding (institution): Biontech; Honoraria (institution), Research grant / Funding (institution): Cepheid. F. Cardoso: Advisory / Consultancy, Research grant / Funding (institution): Amgen; Advisory / Consultancy: Astellas/Medivation; Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy: Celgene; Advisory / Consultancy, Research grant / Funding (institution): Daiichi-Sankyo; Advisory / Consultancy, Research grant / Funding (institution): Eisai; Advisory / Consultancy: GE Oncology; Advisory / Consultancy, Research grant / Funding (institution): Genentech; Advisory / Consultancy, Research grant / Funding (institution): GlaxoSmithKline; Advisory / Consultancy, Research grant / Funding (institution): Macrogenics; Advisory / Consultancy: Medscape; Advisory / Consultancy, Research grant / Funding (institution): MSD; Advisory / Consultancy: Merus BV; Advisory / Consultancy: Mylan; Advisory / Consultancy: Mundipharma; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Pierre-Fabre; Advisory / Consultancy: prIME Oncology; Advisory / Consultancy, Research grant / Funding (institution): Roche; Advisory / Consultancy, Research grant / Funding (institution): Sanofi; Advisory / Consultancy: Seattle Genetics; Advisory / Consultancy: Teva; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Fresenius GmbH; Research grant / Funding (institution): Ipsen; Research grant / Funding (institution): Incyte; Research grant / Funding (institution): Nektar Therapeutics; Research grant / Funding (institution): Nerviano; Research grant / Funding (institution): Medigene; Research grant / Funding (institution): MedImmune; Research grant / Funding (institution): Millenium; Research grant / Funding (institution): Sonus; Research grant / Funding (institution): Tesaro; Research grant / Funding (institution): Tigris; Research grant / Funding (institution): Wilex; Research grant / Funding (institution): Wyeth; Officer / Board of Directors: ESMO Board of Directors. L. Jia: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck & Co., Inc.. V. Karantza: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck & Co., Inc.. J. Zhao: Full / Part-time employment: Merck & Co., Inc.. G. Aktan: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck & Co., Inc.. J. O’Shaughnessy: Honoraria (self): AbbVie Inc; Honoraria (self): Agendia; Honoraria (self): Amgen Biotechnology; Honoraria (self): AstraZeneca; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Celgene Corporation; Honoraria (self): Eisai; Honoraria (self): Genentech; Honoraria (self): Genomic Health; Honoraria (self): GRAIL; Honoraria (self): Immunomedics; Honoraria (self): Heron Therapeautics; Honoraria (self): Ipsen Biopharmaceuticals; Honoraria (self): Jounce Therapeutics; Honoraria (self): Lilly; Honoraria (self): Merck; Honoraria (self): Myriad; Honoraria (self): Novartis; Honoraria (self): Novartis; Honoraria (self): Pfizer; Honoraria (self): Puma Biotechnology; Honoraria (self): Prime Oncology; Honoraria (self): Roche; Honoraria (self): Seattle Genetics; Honoraria (self): Syndax Pharmaceuticals.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings